About All-trans-retinol dehydrogenase [NAD(+)] ADH1B
All-trans-retinol dehydrogenase [NAD(+)] ADH1B (ADH1B) is a protein
from Homo sapiens identified by UniProt accession
P00325, 375 residues long.
MolForge cross-references it against 0 known binders and
284 disease associations.
Target properties
| Protein name | All-trans-retinol dehydrogenase [NAD(+)] ADH1B |
| UniProt accession | P00325 |
| Gene | ADH1B |
| Organism | Homo sapiens |
| Length | 375 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (284)
Diseases linked to this target (Open Targets).
- alcohol dependence · score 0.58
- alcohol consumption measurement · score 0.49
- alcohol use disorder measurement · score 0.49
- alcohol dependence measurement · score 0.48
- alcohol drinking · score 0.46
- lipoprotein measurement · score 0.45
- vitamin D measurement · score 0.44
- longitudinal alcohol consumption measurement · score 0.44
- low density lipoprotein cholesterol measurement · score 0.43
- body mass index · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P00325-F1 | alphafold | PREDICTED | 97.83 | — |
Amino-acid sequence (375 residues)
MSTAGKVIKC KAAVLWEVKK PFSIEDVEVA PPKAYEVRIK MVAVGICHTD DHVVSGNLVT PLPVILGHEA AGIVESVGEG VTTVKPGDKV IPLFTPQCGK CRVCKNPESN YCLKNDLGNP RGTLQDGTRR FTCRGKPIHH FLGTSTFSQY TVVDENAVAK IDAASPLEKV CLIGCGFSTG YGSAVNVAKV TPGSTCAVFG LGGVGLSAVM GCKAAGAARI IAVDINKDKF AKAKELGATE CINPQDYKKP IQEVLKEMTD GGVDFSFEVI GRLDTMMASL LCCHEACGTS VIVGVPPASQ NLSINPMLLL TGRTWKGAVY GGFKSKEGIP KLVADFMAKK FSLDALITHV LPFEKINEGF DLLHSGKSIR TVLTF
Explore All-trans-retinol dehydrogenase [NAD(+)] ADH1B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets